The Latest FDA Q-Submission Final Guidance
Watch the Course Now
Watch the Course Now
About the Course
FDA’s Q-Submission program provides structured pathways for obtaining agency feedback before or during critical stages of medical device development and review. Pre-Subs, Submission Issue Requests (SIRs), Informational Meetings, PMA 100-Day Meetings, and related interactions influence how sponsors address clinical, non-clinical, and regulatory expectations before formal decisions are made. Effective use of these interactions can reduce uncertainty, clarify testing approaches, and strengthen submission quality across IDEs, PMAs, 510(k)s, De Novo requests, CLIA Waivers, and selected CBER-regulated submissions.
Current FDA expectations require organizations to manage Q-Sub communications with clear documentation, consistent follow-up, and well-defined regulatory objectives. This course explains the structure and operational use of the Q-Submission program, including the distinctions between interaction types and their role throughout the device lifecycle. It also addresses submission preparation practices connected to ISO 13485:2016 Clause 7.3 and FDA meeting processes under 21 CFR Part 814.
Key Areas Covered
Quality training, expert insights, and answers that matter. Know your Expert
Ready to Strengthen Your Team? Let’s Build Your Training Plan.
Your team deserves the clarity.
Your organization deserves the confidence.
Upcoming Courses
Your TalkFDA Webinar Experience
1. Confirmation
3. Access course materials
4. Watch The Streaming and Complete your Course
Our students love us ❤️
“Helpful refresher on
Q-Submission interactions and related documentation expectations. Covered the important points without overdoing it.”


